OWLT Healthcare

Owlet, Inc.

$4.23-1.63%

Price as of close on Nov 3, 2026 · Financials updated Oct 10, 2026

Basics

Sector: Healthcare
Industry: Medical Devices
Country: United States
Market cap: 123.6M USD
Enterprise value: 106.2M USD
Full-time employees: 108

Overall health

Strength: growing faster than most peersgrowing faster than peers
Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 1.91 vs a peer median of 0.63), less short-term liquidity (current ratio 1.64 vs a peer median of 2.59) and more debt relative to equity (0.74× vs a peer median of 0.22×)higher risk: bigger price swings (beta 1.91 vs peers 0.63), less liquidity (current ratio 1.64 vs peers 2.59) and more debt vs equity (0.74× vs peers 0.22×)

Ranks #967 of 1,157 healthcare companies (bottom 17%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 255% from December 2022 to August 2026.
Owlet had 255% more shares at August 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Owlet had 255% more shares at August 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Operating loss narrowing. Operating margin -7.8% in 2025, the smallest loss relative to revenue of the last 6 years.
Owlet still lost money on operations in 2025 (margin -7.8%), but that was its smallest operating loss relative to revenue in the 6 years of filings we have.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Owlet looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Growing fast, still losing money. Revenue grew faster than 85% of peers, at an operating loss.
Revenue grew faster than 85% of peers, but the business runs at an operating loss (margin -6.3%).

StockQuotient Score

31/ 100

Oct 5 31 → Nov 4 31

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-7.1%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-6.0%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-6.9%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield18.7%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

81/100

Strong

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

12-month revenue up 7.3%

Why

Stronger than most peers on:

▲ 3-yr revenue
▲ Revenue growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Still loss-making, but the loss per share narrowed33% base weight · Z-score 0.29Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth29.3%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score 2.79Sector median: 0.0584 · MAD: 0.0840

Revenue growth28.2%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 2.27Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

22/100

Weak

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

Operating margin rose 4.1 points to -6.3%

Why

Weaker than most peers on:

▼ ROIC
▼ ROA
▼ Operating margin

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-6.3%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -1.10Sector median: 0.0706 · MAD: 0.1217

Return on assets-9.4%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -2.07Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-61.7%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -6.61Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin54.8%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-38.1%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Beta
▼ Debt / equity
▼ Current ratio

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta1.91

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -3.79Sector median: 0.6250 · MAD: 0.3380

Current ratio1.64×

SEC filings · latest balance sheetReported value33% base weight · Z-score -0.68Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.74×

SEC filings · latest balance sheetReported value33% base weight · Z-score -2.53Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Owlet

Is Owlet getting weaker?: Its latest SEC filing (Aug 14, 2026) got stronger: operating margin rose 4.1 points to -6.3%. Its overall score is unchanged at 31/100 since Oct 28, 2026.
How is Owlet valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -7.1% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -7.1% vs peers 1.5% (weaker than 100% of peers).
Is Owlet growing?: Yes, faster than most of its peers. Growth scores 81/100 against 1,393 healthcare peers. 3-year revenue growth 29.3% vs a peer median of 5.8% (stronger than 87% of peers).3-year revenue growth 29.3% vs peers 5.8% (stronger than 87% of peers).
How profitable is Owlet?: Less profitable than most of its peers. Profitability scores 22/100 against 1,393 healthcare peers. Return on invested capital -61.7% vs a peer median of 4.7% (weaker than 89% of peers).Return on invested capital -61.7% vs peers 4.7% (weaker than 89% of peers).
How risky is Owlet?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 1.91 vs a peer median of 0.63 (weaker than 93% of peers).Beta 1.91 vs peers 0.63 (weaker than 93% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 14, 2026 · compared with the quarter ended Mar 31, 2026

Got stronger

Operating margin rose 4.1 points to -6.3%

	Previous quarter	Latest quarter	Change
Revenue (12 months)	107.1M USD	114.9M USD	+7.3%
Net income (12 months)	−46.0M USD	−8.8M USD	−80.9%
Operating margin	-10.4%	-6.3%	+4.1 pts
Free cash flow (12 months)	−10.2M USD	−8.5M USD	−16.4%
Debt	18.8M USD	17.1M USD	−9.1%
Cash	35.5M USD	30.9M USD	−12.7%
Shares outstanding	29.0M	29.2M	+0.8%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Medical Devices · 33 companies

Valuations in Medical Devices are near the bottom of their range since 2016.

7% of months since 2016 were valued lower than now.
4% of companies are in the most expensive fifth of their own price-to-sales history.
Over 24 months, company values −8% and earnings +33% (medians): earnings grew faster than prices.
Median price-to-sales is +20% vs the whole market, against a usual +109%.

2016Shaded: most expensive fifth of its range2026

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	46.2%	33.7%	41.8%	50.4%	50.6%	▲ 0.3 pts
Operating margin	-73.6%	-122.3%	-53.0%	-25.9%	-7.8%	▲ 18 pts
Net margin	-94.5%	-114.6%	-60.9%	-16.1%	-37.5%	▼ 21 pts
Return on assets (ROA)	-51.2%	-136.5%	-74.6%	-25.3%	-46.3%	▼ 21 pts
Return on equity (ROE)	-129.9%	—	—	—	-208.4%	—
Free cash flow margin	-54.8%	-118.5%	-43.6%	-14.4%	-10.5%	▲ 3.9 pts
Current ratio	1.97×	0.77×	0.89×	1.27×	1.85×	▲ 46%
Quick ratio	1.71×	0.49×	0.74×	0.98×	1.51×	▲ 54%
Debt to equity	0.30×	—	—	—	0.68×	—
Interest coverage	-31.49×	-76.65×	-8.97×	-12.40×	-10.21×	▲ 18%

OWLT price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: growing faster than most peersgrowing faster than peers

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 1.91 vs a peer median of 0.63), less short-term liquidity (current ratio 1.64 vs a peer median of 2.59) and more debt relative to equity (0.74× vs a peer median of 0.22×)higher risk: bigger price swings (beta 1.91 vs peers 0.63), less liquidity (current ratio 1.64 vs peers 2.59) and more debt vs equity (0.74× vs peers 0.22×)

Ranks #967 of 1,157 healthcare companies (bottom 17%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 255% from December 2022 to August 2026.

Owlet had 255% more shares at August 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Owlet had 255% more shares at August 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Operating loss narrowing. Operating margin -7.8% in 2025, the smallest loss relative to revenue of the last 6 years.

Owlet still lost money on operations in 2025 (margin -7.8%), but that was its smallest operating loss relative to revenue in the 6 years of filings we have.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Owlet looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Growing fast, still losing money. Revenue grew faster than 85% of peers, at an operating loss.

Revenue grew faster than 85% of peers, but the business runs at an operating loss (margin -6.3%).

Questions investors ask about Owlet

Is Owlet getting weaker?

Its latest SEC filing (Aug 14, 2026) got stronger: operating margin rose 4.1 points to -6.3%. Its overall score is unchanged at 31/100 since Oct 28, 2026.

How is Owlet valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -7.1% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -7.1% vs peers 1.5% (weaker than 100% of peers).

Is Owlet growing?

Yes, faster than most of its peers. Growth scores 81/100 against 1,393 healthcare peers. 3-year revenue growth 29.3% vs a peer median of 5.8% (stronger than 87% of peers).3-year revenue growth 29.3% vs peers 5.8% (stronger than 87% of peers).

How profitable is Owlet?

Less profitable than most of its peers. Profitability scores 22/100 against 1,393 healthcare peers. Return on invested capital -61.7% vs a peer median of 4.7% (weaker than 89% of peers).Return on invested capital -61.7% vs peers 4.7% (weaker than 89% of peers).

How risky is Owlet?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 1.91 vs a peer median of 0.63 (weaker than 93% of peers).Beta 1.91 vs peers 0.63 (weaker than 93% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

107.1M USD

114.9M USD

+7.3%

Net income (12 months)

−46.0M USD

−8.8M USD

−80.9%

Operating margin

-10.4%

-6.3%

+4.1 pts

Free cash flow (12 months)

−10.2M USD

−8.5M USD

−16.4%

Debt

18.8M USD

17.1M USD

−9.1%

Cash

35.5M USD

30.9M USD

−12.7%

Shares outstanding

29.0M

29.2M

+0.8%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

46.2%

33.7%

41.8%

50.4%

50.6%

▲ 0.3 pts

Operating margin

-73.6%

-122.3%

-53.0%

-25.9%

-7.8%

▲ 18 pts

Net margin

-94.5%

-114.6%

-60.9%

-16.1%

-37.5%

▼ 21 pts

Return on assets (ROA)

-51.2%

-136.5%

-74.6%

-25.3%

-46.3%

▼ 21 pts

Return on equity (ROE)

-129.9%

—

-208.4%

—

Free cash flow margin

-54.8%

-118.5%

-43.6%

-14.4%

-10.5%

▲ 3.9 pts

Current ratio

1.97×

0.77×

0.89×

1.27×

1.85×

▲ 46%

Quick ratio

1.71×

0.49×

0.74×

0.98×

1.51×

▲ 54%

Debt to equity

0.30×

—

0.68×

—

Interest coverage

-31.49×

-76.65×

-8.97×

-12.40×

-10.21×

▲ 18%